目的 探讨心脑联通胶囊联合盐酸阿罗洛尔片治疗不稳定型心绞痛的临床疗效。方法 选择2020年3月—2021年3月在长安医院治疗的172例不稳定型心绞痛患者，根据用药的差别分为对照组和治疗组，每组各86例。对照组口服盐酸阿罗洛尔片，10 mg/次，2次/d；治疗组在对照组基础上口服心脑联通胶囊，2 g/次，3次/d。两组均经40 d治疗。观察两组患者临床疗效和心电图疗效，比较治疗前后两组患者心绞痛情况，心功能，血清学指标碱性成纤维生长因子（bFGF）、血管性血友病因子（vWF）、α颗粒膜蛋白（GMP-140）、组织金属蛋白酶抑制因子1（TIMP1）和转化生长因子β结合蛋白2（LTBP2）水平。结果 经治疗，治疗组临床有效率明显高于对照组（98.84% vs 86.05%，P<0.05）。经治疗，治疗组心电图疗效明显高于对照组（98.84% vs 87.21%，P<0.05）。经治疗，两组心绞痛发作次数、持续时间、硝酸甘油消耗量均显著减少（P<0.05），且治疗组更明显（P<0.05）。经治疗，两组患者内皮依赖性血管舒张功能（FDM）和左心室射血分数（LVEF）明显升高，而左室收缩末期内径（LVESD）和左室舒张末期内径（LVEDD）明显下降（P<0.05），且治疗组心功能明显好于对照组（P<0.05）。经治疗，两组患者血清bFGF、GMP-140和TIMP-1水平明显升高，而vWF和LTBP-2水平明显降低（P<0.05），且治疗组患者血清指标水平明显好于对照组（P<0.05）。结论 心脑联通胶囊联合盐酸阿罗洛尔片治疗不稳定型心绞痛患者不仅促进症状改善，还能够促进机体细胞因子及心功能的改善，具有一定临床推广应用价值。

Objective To investigate the clinical efficacy of Xinnao Liantong Capsules combined with arolol in treatment of unstable angina pectoris. Methods Patients (172 cases) with unstable angina pectoris in Chang'an Hospital from March 2020 to March 2021 were divided into control and treatment group according to different treatments, and each group had 86 cases. Patients in the control group were po administered with Arotinolol Hydrochloride Tablets, 10 mg/time, twice daily. Patients in the treatment group were po administered with Xinnao Liantong Capsules on the basis of the control group, 2 g/time, three times daily. Patients in two groups were treated for 40 d. After treatment, the clinical evaluation and ECG effects were evaluated, the state of angina, cardiac function, the levels of serological indexes bFGF, GMP-140, TIMP-1, vWF and LTBP-2 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (98.84% vs 86.05%, P < 0.05). After treatment, the curative effect of ECG in the treatment group was significantly higher than that in the control group (98.84% vs 87.21%, P < 0.05). After treatment, the frequency, duration and nitroglycerin consumption of angina pectoris in two groups were significantly reduced (P < 0.05), especially in the treatment group (P < 0.05). After treatment, FDM and LVEF were significantly increased, while LVESD and LVEDD were significantly decreased in two groups (P < 0.05), and the cardiac function in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the levels of serum bFGF, GMP-140 and TIMP-1 in 2 groups were significantly increased, while the levels of vWF and LTBP-2 were significantly decreased (P< 0.05), and the serum indexes in treatment group were significantly better than those in control group (P < 0.05). Conclusion Xinnao Liantong Capsules combined with arolol in treatment of unstable angina pectoris can not only promote the improvement of symptoms, but also promote the improvement of the cytokines and cardiac function, which has a certain clinical application value.

R972

陕西省自然科学基础研究计划项目（2021JQ-349）